Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Clinical trial NCT03059992 · COMPLETED

Trial details

NCT number: NCT03059992
Sponsor: Scynexis, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Invasive Candidiasis Mucocutaneous Candidiasis Coccidioidomycosis Histoplasmosis Blastomycosis Chronic Pulmonary Aspergillosis Allergic Bronchopulmonary Aspergillosis Invasive Pulmonary Aspergillosis Recurrent Vulvovaginal Candidiasis Other Emerging Fungi

Start date: 2017-04-01
Primary completion: 2023-08-25
Enrollment: 233

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.